Understanding how the gut microbiome shapes childhood health outcomes has never been more urgent — autism spectrum disorder, pediatric obesity, and malnutrition are all rising globally, and mounting evidence implicates early-life microbial communities in each. A comprehensive mapping of this field now reveals both striking momentum and structural weaknesses that could slow translation into clinical practice.
A bibliometric analysis spanning 15 years (2010–2025) catalogued 1,915 publications drawn from the Web of Science Core Collection, encompassing 12,308 authors across 546 journals, with nearly 40,000 cited references and 3,510 unique keywords. China and the United States together dominate output in a so-called "dual-core" configuration, yet only 27% of studies involved multi-country collaboration — a figure that signals significant fragmentation for a field requiring diverse population data. Research concentration has clustered heavily around ASD, obesity, and nutritional disorders, while developmental and behavioral outcomes beyond ASD appear comparatively underexplored, representing a notable evidence gap.
This analysis arrives at an inflection point for pediatric microbiome science. The surge in publication volume mirrors a broader arc: probiotic and prebiotic interventions have proliferated in clinical trials, yet effect-size heterogeneity remains high and standardized protocols are scarce — problems that geographic siloing only compounds. The dominant role of China and the US, with limited low- and middle-income country participation, raises questions about generalizability, since gut microbiota composition is heavily influenced by diet, geography, and early-life antibiotic exposure. Bibliometric studies like this one are inherently structural rather than causal — they map the intellectual landscape without adjudicating which interventions actually work. Still, the identification of under-researched phenotypes (developmental and behavioral outcomes beyond autism) and the quantified collaboration deficit provide a legitimate roadmap for funders and research consortia. For a field with genuine therapeutic promise — particularly around early microbiome seeding and its lifelong downstream effects — closing these structural gaps is arguably as important as any individual trial result.
